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Current models of rheumatoid arthritis (RA)' implicate lymphokines in the
recruitment and activation ofT cells in the synovium (1, 2) . However, adequate
documentation of significant amounts of these proteins in the joint is limited . In
fact, recent studies have found only very low levels of IFN-y in synovial fluid (SF)
and tissue of patients with RA (3) . This relative lack of IFN-y seems contradictory
in light of morphologic and immunohistochemical evidence of T cell activation in
the RA synovium (4-6) .
Because of this paradox, we decided to study two other T cell lymphokines (IL-2
and IL-3) in rheumatoid synovitis . In this study, we report that neither IL-3 RNA
transcript nor IL-2 could be detected in rheumatoidjoint samples . However, colony-
stimulating factor (CSF) and mast cell growth factor(MCGF) were observed. These
data support the notion that T cell lymphokines are not abundant in the rheuma-
toid joint and that most soluble inflammatory mediators appear to be produced by
macrophages, synovial lining cells, fibroblasts, and endothelial cells in the synovium .
Materials and Methods
Cytokines .
￿
Human (h) rIL-2,hCSF1(macrophage (M)-CSF), and the hCSFl cDNA were
obtained from Cetus Corp . (Emeryville, CA) . hrIL-3 and hrIL-4 were purchased from Gen-
zyme (Cambridge, MA) . Human recombinant granulocyte/macrophage (GM)-CSF and
hrIFN-y were obtained from Amgen Biologicals (Thousand Oaks, CA) . Murine (m) rIL-3,
hG-CSF, and hIL-1 and the hIL-2-RcDNA were obtained from Lilly Research Laboratory
(LaJolla, CA) . Genetics Institute (Cambridge, MA) provided thehuman IL-3 cDNA . IFN-
a2 (Gxa 01-901-535) was obtained from the National Institutes of Health, Bethesda, MD.
Animals.
￿
For CSF assays, 4-12-wk-old CBA/J mice were used . ForMCGF assays, 4-12-
wk-old BALB/c mice were used .
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Patients.
￿
Materials from patients with active classic or definite RA (7) or other forms of
chronic inflammatory synovitis, such as psoriatic arthritis, Reiter's syndrome, and ankylosing
spondylitis, were studied. Joint aspirations were only performed if clinically indicated; in-
formed consent was obtained before the procedure in accordance with Human Subjects Com-
mittee requirements.
SF andST Supernatant Preparations.
￿
SF was aspirated aseptically into heparinized syringes
from the knee joint of patients with active arthritis. The fluid was separated from cells by
centrifugation at 400 g and frozen at -70°C until assayed. ST supernatants were prepared
as previously described (3). Briefly, rheumatoid tissue obtained at the time oftotaljoint replace-
ment surgery was digested for 3 h with collagenase and DNase (Sigma Chemical Co., St.
Louis, MO) at 37oC. The resultant single cell suspension was washed and filtered through
a nylon mesh and the red cells were lysed with hypotonic PBS. Cells were cultured at a den-
sity of 2-3 x 106/ml in RPMI 1640 supplemented with 10% FCS (Gibco Laboratories,
Grand Island, NY) for 3 d at 37oC and 5% C02. Supernatants were harvested and filtered
after 3 d and frozen at -70'C until assayed.
IL-2 Bioassay.
￿
4 x 103 CTLL cells (8) were cultured in microtiter wells in 100 ul of DME
(Gibco Laboratories) plus dilutions of the test sample for 28 h. [3H]TdR was added for the
final 4 h ofculture. Cells were harvested and thymidine uptake was determined in a scintilla-
tion counter. In some experiments, the mAb PC61 (9) was preincubated with the cells at
37°C for 30 min before the addition of test sample in order to block IL-2-R.
IL-2 Immunoassay.
￿
Microtiter wells were coated with 50 wl of mAb to hIL-2 overnight
at 4°C. The wells were then blocked with 5 % casein for 18 h at 4oC. After plates were washed
with PBSTween, 50 wl of each sample was added to duplicate wells and incubated at 37oC
for 2 h. After washing with PBSTween, rabbit anti-h IL-2 (Genzyme) diluted in 5 17o casein
was incubated in the wells for 2 h at room temperature. Plates were again washed and goat
anti-rabbit antibody conjugated to alkaline phosphatase was incubated in wells for 2-3 h
at room temperature. After washing, 50 wl ofp-nitrophenyl phosphate (1 mg/ml) (Sigma Chem-
ical Co.) was added. Plates were read on a micro-ELISA reader (Dynatech Laboratories, Inc.,
Chantilly, VA) at a wavelength of 405 nm. rIL-2 was used as a positive control.
MCGF assay.
￿
Bone marrow cells from BALB/c mice were grown for 3 wk in flasks con-
taining RPMI 1640 plus 10% FCS and 20% WEHI-3 supernatant (containing mIL-3). Ap-
proximately 99% ofviable cells were mast cells as shown by morphology and toluidine blue
stain in acid. Mast cells were resuspended in RPMI 1640 plus 10% FCS and 5 x 104 were
cultured in quadruplicate wells at 37oC and 5olo C02 for 48 h. Cells were pulsed with
[3H]TdR during the final 18 h, harvested, and counted on a scintillation counter.
Murine CSFAssay.
￿
Bone marrow cells were harvested from CBA/J mice and washed in
DME plus 10% FCS. Adherent cells were removed by incubating the cells in plastic petri
dishes for 1-2 h at 37oC and 5% C02. 2 .5 x 105 nonadherent cells were resuspended in
2.5 ml of modified Iscove's medium, 10-5 M 2-ME, 1% methy1cellulose, 25% FCS, and test
factor. SF were tested at a 1 :10 dilution and ST supernatants were tested at either a 1 :10
or 1 :5 dilution. 1 ml of the suspension was added to duplicate 35-mm petri dishes and cul-
tured at 37oC and 5% CO in a humidified incubator. Colonies (>50 cells) were counted using
an inverted microscope on day 10. In some experiments the cells were fixed to slides using
a cytospin apparatus and were stained with Wright-Giemsa stain.
Characterization ofCSFandMCGF.
￿
SF or ST supernatant was concentrated two- to fivefold
and fractionated on a 75 cm x 1.5 cm Sephadex G-100 column at 4oC. Each 3-ml fraction
was assayed for CSF and MCGF
Riboprobe Protection Assay.
￿
Riboprobe protection assays were performed as previously de-
scribed (10). Briefly, synovial cells were solubilized in 7.6 M guanidine hydrochloride (J. T.
Baker Chemical Co., Phillipsburg, NJ), 100 mM potassium acetate (Sigma Chemical Co.),
0.5% n-lauroyl sarcosine (Sigma Chemical Co.), 100 mM 2-ME (SigmaChemical Co.). RNA
was precipitated by the addition ofethanol. RNA probes were prepared using linearized DNA
template, cold nucleotides, a-[32p]UTP (ICN Pharmaceuticals, Inc., Irvine, CA), and SP6
polymerase (Promega Biotech, Madison, WI). The RNA from 106 cells was hybridized with
a-32ltlabeled RNA probes in 80% formamide overnight at 42°C. Unhybridized probe was
then digested with ribonuclease A and incubated with proteinase K (both from SigmaChem-FIRESTEIN ET AL.
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ical Co.). Theprotected fragmentsofprobewerephenol/chloroformextracted, ethanolprecipi-
tated, and resolved on a 6% 20:1 acrylamide/bis-acrylamide sequencing gel. The gel was
exposed at -20°C using Kodak XAR film and an intensifying screen.
Radioimmunoassay.
￿
A specific RIA for measuring CSF (CSF1) was performed under the
direction of Dr. Peter Ralph at Cetus Corp.
Statistics.
￿
Statistical analysis was performed using Student's t test. Dataare presented as
mean f SEM.
Results
Low Levels ofIL-2 in RA SF
Bioassay.
￿
The IL-2-dependent murine cell line CTLL was incubated with var-
ious concentrations of hrIL-2 . As shown in Fig. 1 A, there was a saturable, dose-
dependent increase cell proliferation, as assessed by [3H]TdR incorporation. When
cells were preincubated with the mAb PC61 (which competitively blocks the IL-2-
R), therewas no effect in the presence ofsaturatingamounts ofIL-2. At lower con-
centrations of IL-2, PC61 inhibited IL-2-induced CTLL proliferation. Using this
method, 14 RA SF were assayed for IL-2 activity. Six (43%) induced a significant
increase in thymidine uptake (greater than three times medium control). Preincu-
bation of cells with PC61 had no effect on proliferation induced by any of the six
positive samples (see Figs. 1, B and C, for representative experiments). Therefore,
the CTLL-stimulating activity in SF was not IL-2.
Immunoassay.
￿
A specific ELISAfor IL-2wasused to confirm thebioassay results.
This assay can detect 25-50 pg/ml ofhrIL-2 (3 x 106 U/mg). Using this method,
the supernatants ofPMA (Sigma Chemical Co.)-stimulated HUT cells (a human
T cell line) were found to contain -10 ng/ml of IL-2. 15 RA SF samples were as-
sayed using the ELISA (including 2 that were positive in the CTLL proliferation
assay) and no IL-2 was detected.
Growth Factor Activity in SF
When these experiments were initiated, testing for IL-3 was problematic because
human IL-3 had notbeen identified and no reliable assaywas available. Inthe mouse,
however, it was known that IL-3 had many activities, including the ability to func-
tion as a multilineage colony stimulating factor as well as to stimulate mast cells
andIL-3-dependent leukemic celllines (11). Extrapolating from studies in mice, two
assays were used to study synovial fluids; namely a CSF assay using bone marrow
of mice and a murine MCGF assay.
Proliferation ofMurine BoneMarrow Mast Cells.
￿
A cell population containing >997o
mast cellswas preparedbycultivatingmurine bone marrow in thepresence ofWEHI-3
supernatant (which is a rich source ofmIL-3) for3wk. These mast cells proliferated
in response to mrIL-3 and WEHI-3 supernatant but not to hrIL-1R, IL-2, IL-4,
CSF1, GM-CSF, G-CSF, IFN-y, IFN-a, LPS, or PHA (datanot shown). The results
ofexperiments assayingjoint samples for MCGF activity are summarized in Table
I. As expected, the WEHI supernatant was apotent stimulator ofmast cell prolifer-
ation. A representative dose response is shown in Fig. 2 A. 20 RA samples were
assayed (three representative dose responses are shown in Fig. 2 B). [3H]TdR up-
take was significantly greater for RA SF (2,910 t 328 cpm) compared with either
plasma or medium controls (p < 0.001). Ofthe 20 rheumatoid fluids tested, 8 fluids
were studiedwith extensive serial dilutions. In 4ofthese, proliferation was relatively1576
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FIGURE 1. IL-2 assay . CTLL
cells were cultured with serial di-
lutions ofIL-2 or test sample for
28 h and pulsed with [3H]TdR
for the last 4h . In some experi-
ments, cells were preincubated
withmAbPC61, which binds to
themIL-2-Rand competes with
both human and mIL-2 . (A)
Dose-response curve for IL-2
with andwithoutPC61 . (B and
C) Representative examples of
dose-response curves for (SF)
that stimulated CTLL prolifer-
ation . Preincubation of cells
with PC61 did not block prolif-
eration .
low at high concentrations ofSF and did not peak until at least a 1:16 dilution (see
Fig. 2Bfortwoexamples) . This has twoimplications : First, the level ofproliferation
at low concentrations ofSF approached that ofWEHI supernatant, which suggests
that substantial quantities ofMCGF are present . Second, an inhibitor ofMCGF
interferes with the mast cell proliferation at high concentrations of SF.
Two supernatants of cultured RA ST were assayed . Both significantly increased
mast cell proliferation (see Table I) . The MCGF activity was not found exclusively
in RA samples . Rheumatoid variant SF were also positive, but the level of prolifera-FIRESTEIN ET AL .
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TABLE I
Mast Cell Growth Factor Assay
Sample
￿
[3H]TdR uptake
cpm
Medium (n = 7)
￿
493 t 67
" p < 0.001 compared with medium and p < 0.05 compared with RV SF .
$ p < 0.001 compared with medium .
S RV, rheumatoid variant (including psoriasis, Reiter's syndrome, and ankylosing
spondylitis) .
~~ OA, osteoarthritis .
tion (1,246 t 156 cpm) was less than that forRA SF (,6<0.05) . Noninflammatory
osteoarthritis SF did not support mast cell proliferation .
CSFAssay UsingMurine Bone Marrow.
￿
SF andST were assayed forCSF activity
on nonadherent bone marrow cells from CBA/J mice . After 10 d, colonies (>50 cells)
were counted (see Table II) . hrGM-CSF had no effect on murine marrow cell colony
FIGURE 2 .
￿
Mast cell proliferation assay . (A)
Dose-response curve ofWEHI-3 supernatant
(IL-3) on murine mast cells. Murine bone
marrow-derived mast cells (see text) were cul-
tured for 48 h with serial twofold dilutions of
WEHI supernatantor test sample. Cells were
pulsed with [ 3H]TdR for the last 18 h. (B)
Representative examples ofRA SF dose re-
sponses on murine mast cells .
Normal plasma (n = 4)
WEHI 1 :2 (n = 6)
WEHI 1 :16 (n = 6)
WEHI 1 :32 (n = 7)
520 t 128
31,710 ± 4,040
5,478 t 688
2,318 t 250
RA SF (n = 20) 2,910 t 329"
RA ST (n = 2) 2,965
RV4 SF (n = 7) 1,246 t 1561
OA 11 SF (n = 3) 736 t 1001578
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TABLE II
Efect ofST and SF on Murine Bone Marrow
` Colonies counted after 10 d . Data expressed as mean number of colonies per
105 cells in duplicate cultures .
formation, although human G-CSF (data not shown) and CSR1 were active . Five
RA SF samples were tested in theCSF assay, and four were positive (see Table II) .
All five supernatants from RA ST supported colony growth . Three of the five RA
SF and 2/5 RA ST had been previously tested for MCGF and all were positive .
Colonies appeared between days 3 and 5 and persisted for >2 wk . Some disease
specificity was suggested by the finding that none of the three psoriatic SF tested
were positive . When individual colonies were selected from RA fluid cultures and
stained, most were found to contain macrophages, although some mixed colonies
containing both granulocytes andmacrophages were occasionally identified . Because
the factor was produced by ST explants, it would appear to be made locally. In sup-
port of this, we found that four RA and three normal serum samples were negative
in theCSF assay despite the fact that one of these patients had high CSF activity
in SF (120 colonies/105 cells) .
Characterization ofCSF andMCGFActivity in RA SF .
￿
While these studies were in
progress, thehIL-3 gene wascloned (12) andtherecombinantproduct wasproduced .
To our surprise, hrIL-3 did not stimulate either murine mast cells or murine bone
marrow cells . This species specificity meant that the factors detected in the mast
cell proliferation assay and theCSF assay were distinct from hrIL-3 . Therefore, we
attempted to characterize the factor(s) by Sephadex column chromatography. The
material responsible for colony stimulation and mast cell growth were distinct . Fig .
3 demonstrates the results from one of three different experiments . When colony
formation was measured with mouse bone marrow cells, two major peaks of CSF
activity were observed, with mol wts of -40 and 100 x 10 3 . In another experiment
using concentrated, pooled SF from five RA patients, a third minor peak was ob-
served at a mol wt of -25 x 103 (data not shown) .
The MCGF was considerably smaller, with a mol wt of N6 x 103 (see Fig . 3 B) .
This activity was heat and acid stable and was resistant to trypsin digestion (data
not shown) . As suggested by the biphasic dose responses in Fig . 2 B, high molecular
weight inhibitors ofmIL-3 (see Fig . 3C and hMCGF (data not shown) were also
present in RA SF In this experiment, known amounts of mIL-3 or MCGF were
added to mast cells in the presence of various column fractions. Inhibitory activity
was present in the high molecular weight fractions . It is not known whether this
Sample Colonies/105 Cells*
Medium 0
mIL-3 (100 U/ml) 110
hGM-CSF (80 U/ml) 0
hCSF-1 (50 U/ml) 34
RA SF (n = 5) 34 t 24
RA ST (n - 5) 21 ± 5
Psoriatic SF (n = 3) 0
RA serum (n = 4) 0
Normal serum (n = 3) 0FIRESTEIN ET AL .
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FIGURE 3 .
￿
Fractionation ofRA SF . 2 ml of
SF were concentrated fourfold and fraction-
ated by Sephadex G-100column chromatog-
raphy. Size standards at top are aligned for
all three assays illustrated . (A)CSF . SF frac-
tions (20% by volume) were added to dupli-
cate cultures of murine nonadherent bone
marrow cells . Colony count represents sum
of colonies after 10 d. (B)MCGE Mast cell
proliferation assay performed as in Fig . 2
using 1:16 dilution ofeach fraction. (C)mIL-3
inhibitor. Mast cell proliferation assay per-
formed as in Fig . 2. In each well, WEHI su-
pernatant (1 :8 dilution)wasadded alongwith
1 :16 dilution of SF fractions.
is due toa specific inhibitoror atoxicconstituent of SF, but it is probably the reason
that high concentrations ofSF were less active than dilute SF in the mast cell assay .
Identification oftheCSFPresent in the Rheumatoidjoint.
￿
The predominance ofmac-
rophage colonies and the lack of species specificity suggested that the primaryCSF
in joint effusions detected in the murine assay is CSF1 . Furthermore, CSF1 has
similar molecular weights (36-52 x 103, 70-90 x 103) to the CSF in SF (40 and
100 x 103). These different forms ofCSF1 are due to variablemRNA splicing and
glycosylation (13) . To confirm thepresence ofCSF1, aspecific RIA wasused to mea-1580
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sure CSF1 levels in two ST supernatants and two RA SF samples . The RIA was
positive in each case and correlated with the results of the bioassay (see Table III) .
To positively identify the CSF detected in the murine bone marrow assay as CSF-1,
ST supernatants were preincubated with aneutralizingmAb toCSF1 (14) andwere
subsequently assayed for residual CSF activity (see Table IV). The majority of the
CSF activity was neutralized in two of the three samples tested (the colony count
for ST 25 was too low to determine a neutralizing effect accurately). The antibody
alone had no effect on murine bone marrow cells and did not inhibit colony forma-
tion induced by murine IL-3 (data not shown) . Finally, RA synovial RNA was as-
sayed forCSF1 mRNA using a ribonuclease protection assay . Four of five tissues
assayed contained CSFI transcript (Fig . 4 shows two positive tissues) .
Human Rheumatoid Synovium Does Not Contain Detectable IL-3 mRNA .
￿
The growth
factor bioassaysused in these experiments detected CSF1 and alowmolecular weight
MCGE Because no immunoassays or bioassays are available that are specific for
human IL-3, we attempted to measure IL-3mRNA in RAST cellsusinga sensitive
and specific ribonuclease protection assay. As a positive control, the tissues were
firstassayed forIL-2-R transcript (see Fig. 5 A) . The appropriate 170-base fragment
was protected by synovial RNA, indicating the presence of IL-2-R mRNA. Fig . 5
B shows several of the same tissues assayed for IL-3 mRNA . In this case, the 190-
base IL-3 probe fragment protected by stimulatedJurkat cells (aTcell line) or acti-
vated normal PBMC (data not shown) was not protected in any of the ST assays .
Therefore, IL-3 mRNA was not detected in RA synovium (<1-10 messages per cell
Discussion
A conventional view of rheumatoid synovitis implicates activated inflammatory
cells that indiscriminately secreteavariety of cytokines (1) . T cell products in partic-
ular are thought to be pivotal in this cascade . However, when levels of cytokines
are actually measured, the cytokine milieu is not as complex as initially perceived ;
instead a restricted pattern of lymphokine production emerges . For instance, IL-3
(or at least its mRNA) is undetectable . IFN-7, a plentiful constituent in superna-
tants ofT cells stimulated with antigens or lectins, is virtually absent from ST and
SF (3, 15) . The amount of IL-2 in the rheumatoid joint is controversial; using bioas-
says some investigators have observed IL-2-like activity (16-18), while others have
not (19-21) . This discrepancy is likely due to non-IL-2 cell growth factors present
in the joint. Using an antibody to the IL-2-R and a specific immunoassay, we ob-
TABLE III
CSF-1 Radioimmunoassay
Colonies counted after 10 d .
x JB, XS, RB, SW : initials of patients.
Sample CSF-1 (ng/ml) Colonies/10 5 cells'
Medium <1.5 0
SF JBt 25 120
SF XS 6.3 ND
ST RB 2.3 30
ST SW 1 .6 20FIRESTEIN ET AL .
￿
1581
TABLE IV
Effect ofAntibody to CSF-1 on Synovial Tissue Supernatant CSF
Sample
￿
Colonies/105 cells`
CSF-1 50 U/ml
￿
64
CSF-1 + anti-CSF-11
￿
20
ST Z
￿
53
ST Z + anti-CSF-1
￿
13
ST SW
￿
51
ST SW + anti-CSF-1
￿
15
ST 25
￿
14
ST 25 + anti-CSF-1
￿
9
' Mean number of colonies in duplicate cultures minus mean number of colo-
nies in control dishes . Anti-CSF-1 antibody alone did not affect control dish
colony formation and did not affect mIL-3-supported colony formation .
1 Samples were preincubated with antibody (100 U/ml neutralizing titer) for 60
min at 4°C before adding culture .
served a CTLL stimulating activity in the joint distinct from IL-2 . This activity
has not yet been characterized, but is unlikely to be IL-4 because murine cells do
not respond to the human factor.
There are two caveats regarding the negative results in the IL-2 assays. First, an
inhibitor of IL-2 has been demonstrated in RA SF (22) . This could interfere with
a bioassay, but the inhibitor only diminishes the response of the indicator cells to
IL-2 by N50° / . instead of eliminating it entirely . Also, it is only present in low con-
centrations in SE Because our CTLL assay detects as little as 1 pg/ml of IL-2, it
is unlikely that significant levels of IL-2 would be masked by this inhibitor. Also,
theimmunoassayconfirms the results ofthe bioassay.A second andpotentially more
important possibility is that high levels of IL-2 are produced but the lymphokine
is absorbed by activated cells . This could not be ruled out by the experiments per-
formed in this study, but in situ immunofluorescence studies ofRA synovium has
demonstrated little IL-2, consistent with our observations (15) . On the other hand,
a recent study reported finding IL-2 mRNA in SF mononuclear cells and ST cells
(23), but it is not known whether these cells actively secreted IL-2 . Regardless of
the fate of IL-2 that is secreted into the joint, we have established that the steady-
state levels of IL-2 in SF are negligible.
In contrast to the conspicuous absence of IFN--y, IL-2, and IL-3, several new ac-
tivities were identified in joint tissues and effusions . The majority of RA SF and
ST supernatants contain a low molecular weight MCGE TheMCGF may repre-
sent another member of a class of small immunomodulating peptides, which in-
FIGURE 4 .
￿
CSF-1 mRNA is present in RA synovial tissue. The
full-length probe is 311 bases and CSR1 mRNA protects a 210-
base fragment fromRNAse digestion . Lane 1, unstimulated U937
RNA (negative control) ; lane 2, PMA/ionophore-stimulated U937
(positive control) ; lane 3, ST 5 ; lane 4, ST6 .1582
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FIGURE 5 .
￿
Ribonuclease protection assays ofST RNA . RNA was purified from digested ST
(see MaterialsandMethods). (A) IL-2-RmRNA is present inRA ST cells. IL-2-R probe produces
a protected fragment of -170 bases. Lane 1, IL-2-R probe ; lane 2, ST 1 ; lane 3, ST 2 ; lane
4, ST 2 stimulated with 1 jig/ml PHA for 3 d; lane 5, ST 3 ; lane 6, normal PBM stimulated
with 1 gg/ml PHA for 1 d . (B) IL-3 mRNA is not detected in RA ST cells . M, size markers;
lane 1, IL-3 probe ; lane 2, stimulated Jurkat cells; lane 3, ST 1 ; lane 4, ST 2; lane 5, ST 2
stimulated with PHA for 3 d ; lane 6, ST 3 ; lane 7, ST 4 .
cludes CTAPsand neutrophil migration inhibitory factors . The presence ofMCGF
could explain the local accumulation ofmast cells in rheumatoid synovium and SF .
Mast cells are a rich source of proteases and inflammatory mediators, like hista-
mine, and mayplay a role in acute and chronicsynovitis . An inhibitor of theMCGF
was also identified in SE Local inhibition ofMCGF by this factor may represent
a negative feedback loop similar to those previously described for IL-1, IL-2, and
IFN-y (3, 22, 24) .FIRESTEIN ET AL.
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Inflammatory joint fluids also contain colony-stimulating activity. For instance,
we recently demonstrated GM-CSF in inflammatory SF (Xu, W. D., G. S. Fire-
stein, R. Taetle, K. Kaushansky, and N.J. Zvaifler, submittedforpublication). Human
GM-CSF is species specific, however, and can not account for the CSF identified
in this study. Using murine bone marrow cells the majority ofthat activity is due
tolocally produced CSF1. The role ofCSFs in therheumatoid process isnot under-
stood, but their spectrum ofactivity extends beyond the induction ofcolony forma-
tionfrom immatureprecursors, sincemanyofthesefactor;haveotherimmunomodula-
toryfunctions. GM-CSF, for example, increasesboth IL-1 secretion andIaexpression
inmurine macrophages(25) and CSF1 increasesmacrophage TNFproduction (26).
Therefore, combinations ofCSFs may either directly activate APCs orprime them
for triggering by other cytokines, thus enhancing synovitis.
To date, mostofthemediators identified in synovial fluid or synovial tissue super-
natants appear tobe produced bynon-Tcells. Monocytes andmacrophages arelikely
sources ofTNF (27), CSF1 (28), GM-CSF (29), IL-1 (30), and IL-1 inhibitors (24),
aswell as prostaglandins (31) and collagenase (32). Hence, macrophage, endothelial
cell, or synoviocyte activation seems to be crucial to the immunological reactivity
ofthe rheumatoid synovium. When one views the data on synovial ultrastructure
in RAfromthisperspective, the evidence forT cell activation islimited. Most syno-
vial T cells are small and quiescent in appearance, expressing very little surface Ia
(33). Although IL-2-R are present on some cells, the degree ofexpression at the
mRNA level is comparable to that of resting peripheral blood T cells rather than
mitogen-stimulated cells (our unpublished data). This is in sharp contrast to the
activated appearance ofmacrophages, which express high levels of membrane la
(33, 34). Although indirect evidence (such as the observation thatRA may improve
after thoracic duct drainageortotalnodal irradiation) suggests that T cell activation
is important in rheumatoid synovitis, the cytokine profile of SF and inflamed ST
supports the notion that macrophage activation may be a primary event in RA.
Summary
Because previous studies showed low levels ofIFN-7 in rheumatoid arthritis (RA)
synovial fluid (SF) and synovial tissue (ST) explant supernatants, we assayed RA
SFand ST for IL-2 and IL-3-like activity. Using an IL-2 dependent murine CTLL
line, 6 of 14 RA SF caused increased thymidine uptake (greater than three times
control). The activity was distinct fromIL-2 becauseit was notblocked by antibody
to IL-2-R. In addition, IL-2 was not detected (<50 pg/ml) in 16joint samples using
an ELISA. Multi-colony-stimulating factor (CSF) activity wasmeasured using two
assays that can detect murine IL-3 (mast cellproliferation, and bone marrowCSF).
In the mast cell assay, [3H]TdR uptake was 493 t 67 cpm for medium, 2,910 t
329 cpm in the presence of RA SF (p < 0.001), 1,246 t 156 cpm in the presence
of SF from patients with seronegative spondyloarthropathies (p < 0.001), and 736
± 100 cpm in the presence of osteoarthritis SF (p > 0.1). In the CSF assay, four
offive RA SF and five offive RA ST induced colony formation from bone marrow
nonadherent cells. Macrophage colonies were most common, although mixed colo-
nies and granulocytes were occasionally observed. The multi-CSF activity in RA
is not due to IL-3 since human rIL-3 was not active in either murine assay, and
IL-3 mRNA was not detected in RA synovium. Sephadex column chromatography1584
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of RA SF revealed that the mast cell growth factor (ti6 x 103 mol wt) and the CSF
(-40 and 100 x 103 mol wt) are distinct. The colony-stimulating aspect of the "IL-
3-like" activity in RA SF is likely due to CSF1 because it is the appropriate mol
wt and because the activity was neutralized by specific anti-CSFI antibody. Finally,
an RIA detected 1.6-25 ng/ml of CSF1 in RA SF and ST and CSF1 mRNA was
detected in four of five RA synovial tissue samples tested.
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